China, with its rapidly aging population, stands as one of the leading medical device markets globally. The country's long-term health governance plans aim to expand healthcare services and financial coverage, predicting a significant rise in healthcare expenditure in the years ahead.
This growth presents substantial opportunities for medical device companies looking to obtain NMPA China medical device registration and approval.
China’s medical devices market is set to reach $40.96B by 2025, growing at 7.98% CAGR (2025–2029). The IVD market will hit $23.81B by 2030, with 5.01% CAGR (2025–2030), driven by chronic diseases, tech advancements, and an aging population.
China's medical device regulatory is the National Medical Products Administration (NMPA). Pure Global can assist with China medical device registration and act as your China Agent, ensuring NMPA approval to sell in the Chinese market.
Medical devices in China are classified into Class I, II, and III, reflecting an ascending order of risk. Class I devices enjoy a more streamlined registration process, while Class II and III devices may require local clinical trials and in-country testing, depending on specific conditions such as having exact predicates or being listed on NMPA's clinical trial exemption list.
Entering the Chinese market necessitates:
Leverage our expertise for a smooth market entry into China:
Guidance on classifying your products and outlining the regulatory pathway.
Assistance with compiling the regulatory dossier and navigating local testing and clinical study requirements when applicable.
Acting as your China Agent for NMPA registration, ensuring compliance with post-market requirements.
The primary regulatory authority for medical device registration in China is the National Medical Products Administration (NMPA). Pure Global can assist with navigating the registration process to ensure NMPA approval for selling medical devices in the Chinese market.
Medical devices in China are classified into Class I, II, and III based on their risk level. Class I devices typically undergo a more straightforward registration process, while Class II and III devices may require local clinical trials and in-country testing, depending on specific conditions such as predicate devices or listing on NMPA China's clinical trial exemption list.
Foreign manufacturers must: Classify their products to determine the regulatory pathway and understand local clinical study and testing requirements. Compile a comprehensive regulatory dossier for submission to the National Medical Product Administration (NMPA), demonstrating compliance with Chinese regulatory standards. For Class II and III devices, conduct local clinical trials unless exemptions apply, such as having exact predicates or being listed on NMPA's clinical trial exemption list.
Having the country of origin's approval is crucial because it demonstrates that the medical device meets regulatory standards in its country of origin. This approval is often a prerequisite for initiating the registration process with NMPA under China medical device regulations, ensuring that the device can legally enter and be marketed in the Chinese market.
When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us
